FindTrial
Sign In

A Parallel Group Phase II Study of KCT-0809 in Patients With Dry Eye Syndromes

A Randomized, Double Blind, Placebo Controlled, Parallel Group Phase II Study of KCT-0809 in Patients With Dry Eye Syndromes

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01692145
Enrollment
Unknown
Registered
2012-09-25
Start date
Unknown
Completion date
Unknown
Last updated
2014-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry Eye Syndromes

Keywords

Dry eye syndromes, Corneal diseases, Conjunctival diseases

Brief summary

The purpose of this study is to evaluate the efficacy and safety of KCT-0809 compared to placebo in patients with dry eye syndromes.

Interventions

DRUGKCT-0809
DRUGPlacebo

Sponsors

Kissei Pharmaceutical Co., Ltd.
Lead SponsorINDUSTRY

Study design

Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Corneal and conjunctival damage * Insufficiency of lacrimal secretion * Ocular symptom

Exclusion criteria

* Severe ophthalmic disorder * Punctual plugs or surgery for occlusion of the lacrimal puncta

Design outcomes

Primary

MeasureTime frame
Score of the Corneal conjunctival staining—

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026